Association of Hypovitaminosis D with chronic kidney disease and bone disorders
Canine chronic kidney disease-mineral and bone disorder (CKD-MBD) has been associated with hypovitaminosis D, increased parathyroid hormone (PTH), and increased fibroblast growth factor-23 (FGF-23) concentrations.
During a prospective study, dogs with stage 2 and 3 of chronic kidney disease were given a calcifediol supplement for 21 weeks. The levels serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, , 24,25-dihydroxyvitamin D, creatinine, calcium, phosphorus, PTH, plasma FGF-23 concentrations, and urine profiles were recorded every month. Other values assessed were the urine calcium to creatinine (UCa/Cr) ratios, and fractional excretion of calcium, phosphorus, and sodium were determined.
Results showed the concentrations 25(OH)D, 1,25(OH)2D, and 24,25(OH)2D were highly increased by the last day of the study compared to baseline concentrations. No major differences were recorded in calcium, phosphorus, PTH concentrations, UCa/Cr, or fractional excretion of calcium. The plasma fibroblast growth factor 23 ( FGF-23) concentrations also were increased by the last day of the study compared to baseline.
This study finds that calcifediol supplementation was well-tolerated in dogs with IRIS stages 2 and 3 CKD for 84 days. However, it has to be evaluated if calcifediol would affect CKD patients in the long-term.
To read more click on the link below:
